Quick Answer
Forte Biosciences, Inc. reported Diluted EPS of $4.71 per share (loss) for fiscal year 2025.
Forte Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.71 | +61.3% |
| 2024 | -$12.17 | +51.2% |
| 2023 | -$24.92 | -3015.0% |
| 2022 | -$0.80 | +48.4% |
| 2021 | -$1.55 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.99 | +78.2% | -3.1% |
| June 30, 2025 | -$0.96 | +85.8% | +29.9% |
| March 31, 2025 | -$1.37 | +66.0% | +69.8% |
| September 30, 2024 | -$4.54 | +30.9% | +33.0% |
| June 30, 2024 | -$6.78 | -1514.3% | -68.2% |
| March 31, 2024 | -$4.03 | -1159.4% | +38.7% |
| September 30, 2023 | -$6.57 | -3550.0% | -1464.3% |
| June 30, 2023 | -$0.42 | -100.0% | -31.2% |
- Forte Biosciences, Inc. showed an increase of +61.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Forte Biosciences, Inc.’s diluted eps has declined by 203.9% (from $1.55 per share (loss) to $4.71 per share (loss)).
- The most recent figure is from Forte Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: